Prognostic value of textural features obtained from F-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in patients with locally advanced cervical cancer undergoing concurrent chemoradiotherapy
Objective To evaluate whether textural features obtained from F-18 FDG PET/CT offer clinical value that can predict the outcome of patients with locally advanced cervical cancer (LACC) receiving concurrent chemoradiotherapy (CCRT). Methods We reviewed the records of 68 patients with stage IIB–IVA LA...
Gespeichert in:
Veröffentlicht in: | Annals of nuclear medicine 2023, Vol.37 (1), p.44-51 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective
To evaluate whether textural features obtained from F-18 FDG PET/CT offer clinical value that can predict the outcome of patients with locally advanced cervical cancer (LACC) receiving concurrent chemoradiotherapy (CCRT).
Methods
We reviewed the records of 68 patients with stage IIB–IVA LACC who underwent PET/CT before CCRT. Conventional metabolic parameters, shape indices, and textural features of the primary tumor were measured on PET/CT. A Cox regression model was used to examine the effects of variables on overall survival (OS) and progression-free survival (PFS).
Results
The patients included in this study were classified into two groups based on median value of PET/CT parameters. The high group of GLNU derived from GLRLM is only independent prognostic factor for PFS (HR 7.142; 95% CI 1.656–30.802;
p
= 0.008) and OS (HR 9,780; 95% CI 1.222–78.286;
p
= 0.031). In addition, GLNU derived from GLRLM (AUC 0.846, 95% CI 0.738–0.923) was the best predictor for recurrence among clinical prognostic factors and PET/CT parameters.
Conclusion
Our results demonstrated that high GLNU from GLRLM on pretreatment F-18 FDG PET/CT images, were significant prognostic factors for recurrence and death in patients with LACC receiving CCRT. |
---|---|
ISSN: | 0914-7187 1864-6433 |
DOI: | 10.1007/s12149-022-01802-z |